Page 94 - 2020_08-Haematologica-web

G. Kooij et al.
rosis: the 2013 revisions. Neurology.
2014;83(3):278-286.
26. Reich DS, Lucchinetti CF, Calabresi PA.
Multiple Sclerosis. N Engl J Med. 2018;
378(2):169-180.
27. Chiurchiù V. Novel targets in multiple scle-
rosis: to oxidative stress and beyond. Curr
Top Med Chem. 2014;14(22):2590-2599.
28. Prüss H, Rosche B, Sullivan AB et al. Proresolution lipid mediators in multiple sclerosis - differential, disease severity dependent synthesis - a clinical pilot trial.
PLoS One. 2013;8(2):e55859.
29. Hsiao H-M, Thatcher TH, Colas RA,
Serhan CN, Phipps RP, Sime PJ. Resolvin D1 reduces emphysema and chronic inflammation. Am J Pathol. 2015;185:3189– 31201.
30. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. Resolvin D1 decreases adipose tis- sue macrophage accumulation and improves insulin sensitivity in obese-dia- betic mice. FASEB J 2011;25:2399–23407.
31. Clària J, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol. 2012;189:2597–25605.
32. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirintriggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol. 2011;187:1957–1969.
33. Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease. Eur J Pharmacol. 2016;785:156– 164.
34. Perretti M, Norling LV. Actions of SPM in regulating host responses in arthritis. Mol Aspects Med. 2017;58:57–64.
35. Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, et al. An imbalance between specialized pro- resolving lipid mediators and pro-inflam- matory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun. 2016;7:12859.
36. Wang X, Zhu M, Hjorth E, Cortés-Toro V, Eyjolfsdottir H, Graff C, et al. Resolution of inflammation is altered in Alzheimer’s dis- ease. Alzheimers Dement. 2015;11:40.e- 50.e.
37. Zhu M, Wang X, Hjorth E, Colas RA, Schroeder L, Granholm A-C, et al. Pro-
resolving lipid mediators improve neuronal survival and increase A 42 phagocytosis. Mol Neurobiol. 2016;53:2733-2749.
38. Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, et al. -3 supplementation increases amyloid- phagocytosis and resolvin D1 in patients with minor cogni- tive impairment. FASEB J. 2015;29:2681- 2689.
39. Holman RT, Johnson SB, Kokmen E. Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. Proc Natl Acad Sci U S A. 1989;86(12):4720- 4724.
40. Poisson LM, Suhail H, Singh J et al. Untargeted plasma metabolomics identifies endogenous Metabolite with Drug-like properties in chronic animal model of mul- tiple sclerosis. J Biol Chem. 2015; 290(52):30697-30712.
41. Jelinek GA, Hadgkiss EJ, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. Association of fish consumption and Ω 3 supplementation with quality of life, dis- ability and disease activity in an interna- tional cohort of people with multiple scle- rosis. Int J Neurosci. 2013;123(11):792- 800.
42. Weinstock-Guttman B, Baier M, Park Y et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 2005;73(5):397- 404.
43. Reder AT, Genc K, Byskosh PV, Porrini AM. Monocyte activation in multiple sclerosis. Mult Scler 1998; 4: 162–168.
44. Chuluundorj D, Harding SA, Abernethy D, La Flamme AC. Expansion and preferential activation of the CD14(+)CD16(+) mono- cyte subset during multiple sclerosis. Immunol Cell Biol. 2014;92(6):509-517.
45. Singh A et al. Lipoxin A4, a 5-lipoxygenase pathway metabolite, modulates immune response during acute respiratory tularemia. J Leukoc Biol. 2017;101(2):531- 542.
46. Gu Z, Lamont GJ, Lamont RJ, Uriarte SM, Wang H, Scott DA. Resolvin D1, resolvin D2 and maresin 1 activate the GSK3 anti- inflammatory axis in TLR4-engaged human monocytes. Innate Immun. 2016;22(3):186- 195.
47. Koltsida O, Karamnov S, Pyrillou K et al.
Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflam- mation. EMBO Mol Med. 2013;5(5):762- 775.
48. Ortiz GG, Pacheco-Moisés FP, Macías-Islas MÁ et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014; 45(8):687-697.
49. Kadl A, Leitinger N. The role of endothelial cells in the resolution of acute inflamma- tion. Antioxid Redox Signal. 2005;7(11- 12):1744-1754.
50. Chattopadhyay R, Raghavan S, Rao GN. Resolvin D1 via prevention of ROS-mediat- ed SHP2 inactivation protects endothelial adherens junction integrity and barrier function. Redox Biol. 2017;12:438-455.
51. Zhang X, Wang Y, Gui P, et al. Resolvin D1 reverts lipopolysaccharide-induced TJ pro- teins disruption and the increase of cellular permeability by regulating I B signaling in human vascular endothelial cells. Oxid Med Cell Longev. 2013;2013:185715.
52. Pang H, Huang YP, Liu ZJ, et al. Effect of lipoxin A4 on lipopolysaccharide-induced endothelial hyperpermeability. Scientific World Journal. 2011;11:1056-1067.
53. Jones CN, Dalli J, Dimisko L, Wong E, Serhan CN, Irimia D. Microfluidic cham- bers for monitoring leukocyte trafficking and humanized nano-proresolving medi- cines interactions. Proc Natl Acad Sci U S A. 2012;109(50):20560-20565.
54. Akagi D, Chen M, Toy R, Chatterjee A, Conte MS. Systemic delivery of proresolv- ing lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015;29(6):2504-2513.
55. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C. Lipoxin A4: anti-inflammato- ry and anti-angiogenic impact on endothe- lial cells. J Immunol. 2009;182(6):3819-26.
56. Chinthamani S, Odusanwo O, Mondal N, Nelson J, Neelamegham S, Baker OJ. Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endotheli- um. Am J Physiol Cell Physiol. 2012; 302(7):C968-C978.
57. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008;22(10):3595- 606.
2070
haematologica | 2020; 105(8)